Zogenix is a pharmaceutical company that was founded in 2006 and is committed to providing innovative treatments for people living with rare and burdensome diseases that affect the central nervous system, such as Dravet syndrome – Zogenix is working with dedicated scientific and medical experts, each of whom share a collective passion for making a difference in the lives of patients they serve.

Visit the Zogenix website to learn more.

Would you like to be kept up-to-date with the latest news about Zogenix’s efforts to treat Dravet syndrome?

Simply complete this form and we’ll send you information as and when it becomes available.


Thank you for your interest in the FAiRE program of clinical studies, your details have been successfully submitted.

Thank you for your interest in the FAiRE program of clinical studies. To receive further information about the program, simply complete this form and our study team will contact you shortly.

Contact preference:


Thank you for your interest in the FAiRE program of clinical studies, your details have been successfully submitted.


Dravet Syndrome Clinical Trials

In brief

Has your son or daughter been diagnosed with Dravet syndrome? Are they still having uncontrolled seizures despite current medication? Then you may be interested in FAiRE (Fenfluramine Assessment in Rare Epilepsy) – a program of clinical studies that will ask if an investigational drug called ZX008 can improve seizure control in children and young adults with Dravet syndrome.

The FAiRE studies will try to answer questions about ZX008 such as:

  • Can it reduce the number of seizures when given alongside other anti-seizure medications?
  • Does it cause any side effects?

Can I take part?


Participants may join study 1501, 1502, or 1504. Each of these studies will try to answer a different question:

  • Participation in studies 1501 and 1502 lasts for up to 22 weeks
  • Participation in study 1504 lasts for up to 26 weeks


To help researchers learn about ZX008 (low-dose fenfluramine), participants will be given a dosing plan to follow for a set amount of time. These dosing plans will differ between studies.

Studies 1501 and 1502 Study 1504

Participants will randomly (by chance) receive:

ZX008 for up to 16 weeks
A placebo (a ‘dummy’ drug) for up to 16 weeks

Participants will be 2 times more likely to receive ZX008 (at one of two different doses) than a placebo.

Participants will randomly (by chance) receive:

ZX008 plus other study medication for up to 19 weeks
A placebo plus other study medication for up to 19 weeks

Participants have an equal chance of receiving either ZX008 or a placebo.

All participants will continue to take their existing anti-seizure medication(s) throughout the study.

Why is this study being conducted?

ZX008 is solution of low-dose fenfluramine taken by mouth.

In the past, higher doses of fenfluramine were approved for obese adults as an appetite suppressant. But it was withdrawn because some people developed serious heart-related side effects. However, ZX008 is a low-dose formulation of fenfluramine. Several children have been treated with low-dose fenfluramine to date (some for up to 26 years). Of those, the majority have experienced no signs or symptoms of heart disease. But the FAiRE program of studies includes an extensive heart-monitoring plan to help identify any early signs of heart-related side effects.

Health checks

All participants will have their health checked regularly. This will be done at the study clinic and over the telephone. During the clinic visits, a study doctor will carry out a range of assessments and lab tests. These will differ from visit to visit, but may include:

  • Electrocardiograms (a painless recording of the heart’s electrical activity)
  • Echocardiograms (a painless ultrasound of the heart – to monitor for any heart-related side effects)
  • Vital signs checks (heart rate, breathing rate, pulse and temperature)
  • Physical examinations
  • Nervous system assessments.


After their final dose, participants will enter a follow-up period. This allows the study team to monitor their health and record what happens once they come to the end of their dosing plan.

Some participants may also be given the option to join an extension study instead of entering the follow-up period. During the extension study, all participants will take ZX008 – even those given a placebo before.

Can I take part?